Clinical characteristics and outcomes of patients with severe left ventricular dysfunction undergoing cardiac MRI viability assessment prior to revascularization.


Journal

The international journal of cardiovascular imaging
ISSN: 1875-8312
Titre abrégé: Int J Cardiovasc Imaging
Pays: United States
ID NLM: 100969716

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 07 06 2020
accepted: 23 09 2020
pubmed: 10 10 2020
medline: 8 6 2021
entrez: 9 10 2020
Statut: ppublish

Résumé

Coronary artery bypass grafting improves survival in patients with ischemic cardiomyopathy, however, these patients are at high risk for morbidity and mortality. The role of viability testing to guide revascularization in these patients is unclear. Cardiac magnetic resonance imaging (CMR) has not been studied adequately in this population despite being considered a reference standard for infarct imaging. We performed a multicenter retrospective analysis of patients (n = 154) with severe left ventricular systolic dysfunction [ejection fraction (EF) < 35%] on CMR who underwent CMR viability assessment prior to consideration for revascularization. Using the AHA16-segment model, percent total myocardial viability was determined depending on the degree of transmural scar thickness. Patients with or without revascularization had similar clinical characteristics and were prescribed similar medical therapy. Overall, 43% of patients (n = 66) experienced an adverse event during the median 3 years follow up. For the composite outcome (death, myocardial infarction, heart failure hospitalization, stroke, ventricular tachycardia) patients receiving revascularization were less likely to experience an adverse event compared to those without revascularization (HR 0.53, 95% CI 0.33-0.86, p = 0.01). Patients with > 50% viability on CMR had a 47% reduction in composite events when undergoing revascularization opposed to medical therapy alone (HR 0.53, p = 0.02) whereas patients with a viability < 50% were 2.7 times more likely to experience an adverse event (p = 0.01). CMR viability assessment may be an important tool in the shared decision-making process when considering revascularization options in patients with severe ischemic cardiomyopathy.

Identifiants

pubmed: 33034865
doi: 10.1007/s10554-020-02042-w
pii: 10.1007/s10554-020-02042-w
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

675-684

Références

Yancy CW, Jessup M, Bozkurt B, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16):e240–e327
pubmed: 23741058 pmcid: 23741058
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, STICH Investigators (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364(17):1607–1616
doi: 10.1056/NEJMoa1100356
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-Nickens P, Sopko G, Rouleau JL, STICHES Investigators (2016) Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374(16):1511–1520
doi: 10.1056/NEJMoa1602001
Petrie MC, Jhund PS, She L, STICH Trial Investigators et al (2016) Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation 134(18):1314–1324
doi: 10.1161/CIRCULATIONAHA.116.024800
Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM (1999) Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100(19):1992–2002
doi: 10.1161/01.CIR.100.19.1992
Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343(20):1445–1453
doi: 10.1056/NEJM200011163432003
Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, Klocke FJ, Bonow RO, Kim RJ, Judd RM (2003) Contrast-enhanced MRI and routine single photon emission computed tomography perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 361:374–379
doi: 10.1016/S0140-6736(03)12389-6
Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London, New York, 201 S., £ 12. Biom J 29:114–114. https://doi.org/10.1002/bimj.4710290119
Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH (2007) Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 32(7):375–410
doi: 10.1016/j.cpcardiol.2007.04.001
Kim RJ, Shah DJ (2004) Fundamental concepts in myocardial viability assessment revisited: when knowing how much is “alive” is not enough. Heart (Br Card Soc) 90(2):137–140
doi: 10.1136/hrt.2003.023101
Kwon DH, Obuchowski NA, Marwick TH, Menon V, Griffin B, Flamm SD, Hachamovitch R (2018) Jeopardized myocardium defined by late gadolinium enhancement magnetic resonance imaging predicts survival in patients with ischemic cardiomyopathy: impact of revascularization. J Am Heart Assoc 7(22):e009394
doi: 10.1161/JAHA.118.009394
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE (2002) Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39(7):1151–1158
doi: 10.1016/S0735-1097(02)01726-6
Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, Hachamovitch R (2013) Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging 6(3):363–372
doi: 10.1161/CIRCIMAGING.112.000138
Mc Ardle B, Shukla T, Nichol G, deKemp RA, Bernick J, Guo A, Lim SP, Davies RA, Haddad H, Duchesne L, Hendry P, Masters R, Ross H, Freeman M, Gulenchyn K, Racine N, Humen D, Benard F, Ruddy TD, Chow BJ, PARR-2 Investigators (2016) Long-term follow-up of outcomes with F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease. Circ Cardiovasc Imaging 9(9):e004331
doi: 10.1161/CIRCIMAGING.115.004331
Inaba Y, Chen JA, Bergmann SR (2010) Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis. J Nucl Cardiol 17:646–654. https://doi.org/10.1007/s12350-010-9226
doi: 10.1007/s12350-010-9226 pubmed: 20379861
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, STICH Trial Investigators (2011) Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 364(17):1617–1625
doi: 10.1056/NEJMoa1100358
Kwon DH, Halley CM, Carrigan TP, Zysek V, Popovic ZB, Setser R, Schoenhagen P, Starling RC, Flamm SD, Desai MY (2009) Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging 2(1):34–44
doi: 10.1016/j.jcmg.2008.09.010
Gerber BL, Rousseau MF, Ahn SA, le Polain de Waroux JB, Pouleur AC, Phlips T, Vancraeynest D, Pasquet A, Vanoverschelde JL (2012) Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J Am Coll Cardiol 59(9):825–835
doi: 10.1016/j.jacc.2011.09.073

Auteurs

Demetrios Doukas (D)

Division of Cardiology, Loyola University Chicago Stritch School of Medicine, and Loyola University Health System, Maywood, IL, USA.

Katerina Porcaro (K)

Division of Cardiology, Loyola University Chicago Stritch School of Medicine, and Loyola University Health System, Maywood, IL, USA.

Jessica Marot (J)

Department of Internal Medicine, Loyola University Chicago Stritch School of Medicine, and Loyola University Health System, Maywood, IL, USA.

Lucas Burke (L)

Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

Cara Joyce (C)

Biostatistics Collaborative Core, Loyola University Chicago, Maywood, IL, USA.

Frances Weaver (F)

Department of Veterans Affairs, Center of Innovation for Complex Chronic Healthcare, Hines, IL, USA.

James Nguyen (J)

Division of Cardiology, The Heart Center, St. Francis Hospital, Stony Brook University, Rosyln, NY, USA.

J Jane Cao (JJ)

Division of Cardiology, The Heart Center, St. Francis Hospital, Stony Brook University, Rosyln, NY, USA.

Verghese Mathew (V)

Division of Cardiology, Loyola University Chicago Stritch School of Medicine, and Loyola University Health System, Maywood, IL, USA.

Alain Heroux (A)

Division of Cardiology, Loyola University Chicago Stritch School of Medicine, and Loyola University Health System, Maywood, IL, USA.

Mushabbar A Syed (MA)

Division of Cardiology, Loyola University Chicago Stritch School of Medicine, and Loyola University Health System, Maywood, IL, USA. masyed@lumc.edu.
Division of Cardiology, Department of Medicine, Loyola University Health System, Loyola University Chicago Stritch School of Medicine, 2160 S 1st Ave, Maywood, Il, 60153, USA. masyed@lumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH